GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver DiseaseGlobeNewsWire • 09/28/20
GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBCGlobeNewsWire • 09/24/20
GENFIT To Announce First Half-Year 2020 Financial Results and New Corporate Strategy on September 30, 2020GlobeNewsWire • 09/22/20
GENFIT Announces Two Oral Presentations at the Digital International Liver Congress™ 2020GlobeNewsWire • 08/26/20
GENFIT Announces Pivotal Publication of NIS4™ Technology to Identify Patients with At-Risk NASH in The Lancet Gastroenterology & HepatologyGlobeNewsWire • 08/05/20
Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage StudyBenzinga • 05/12/20
This Biotech Just Lost Half Its Value After A Key Hepatitis Drug FailedInvestors Business Daily • 05/11/20